Patents by Inventor Michelle Pusey

Michelle Pusey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
    Publication number: 20240041887
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
    Type: Application
    Filed: July 12, 2023
    Publication date: February 8, 2024
    Inventors: Yaoyu CHEN, Matthew C. STUBBS, Ying-Nan Pan CHEN, Michelle PUSEY
  • Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
    Patent number: 11738026
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: August 29, 2023
    Assignee: INCYTE CORPORATION
    Inventors: Yaoyu Chen, Matthew C. Stubbs, Ying-Nan Pan Chen, Michelle Pusey
  • COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
    Publication number: 20210154195
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
    Type: Application
    Filed: November 20, 2020
    Publication date: May 27, 2021
    Inventors: Yaoyu CHEN, Matthew C. STUBBS, Ying-Nan Pan CHEN, Michelle PUSEY
  • PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION
    Publication number: 20200190592
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 18, 2020
    Applicant: Medical Diagnostic Laboratories, L.L.C.
    Inventors: Lyndi Rice, Michelle Pusey, Ewa Wandzioch, Sophie Marie Genevieve Bail, Amy Lynn Werda
  • PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
    Patent number: 10167472
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: January 1, 2019
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Lyndi Rice, Michelle Pusey, Ewa Wandzioch, Sophie Marie Genevieve Bail, Amy Lynn Wenda
  • PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION
    Publication number: 20170226520
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 10, 2017
    Applicant: Medical Diagnostic Laboratories, L.L.C.
    Inventors: Lyndi Rice, Michelle Pusey, Ewa Wandzioch, Sophie Marie Genevieve Bail, Amy Lynn Wenda
  • PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
    Patent number: 9663789
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer and triple negative breast cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: May 30, 2017
    Assignee: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Lyndi M. Rice, Michelle Pusey
  • PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
    Patent number: 9657349
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: May 23, 2017
    Assignee: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Lyndi Rice, Michelle Pusey, Ewa Wandzioch, Sophie Marie Genevieve Bail, Amy Lynn Werda
  • PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE ENDOMETRIAL AND BREAST CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION
    Publication number: 20150284723
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer and triple negative breast cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Application
    Filed: October 15, 2014
    Publication date: October 8, 2015
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Lyndi M. Rice, Michelle Pusey
  • PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION
    Publication number: 20140323546
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Application
    Filed: April 28, 2014
    Publication date: October 30, 2014
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Lyndi Rice, Michelle Pusey, Ewa Wandzioch